Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Pfizer Unit Reaches Patent Litigation With Intelliject, Sanofi-Aventis

RELATED NEWS
Trade MYL now with 

Mylan Inc. (MYL: Quote) and Pfizer Inc. (PFE: Quote) Thursday announced that Meridian Medical Technologies, a Pfizer subsidiary, has agreed with Intelliject and Sanofi-Aventis to resolve pending patent litigation related to Intelliject's new drug application for its epinephrine auto-injector known as e-cue.

E-cue will be manufactured and marketed by Sanofi-Aventis. Meridian manufactures EpiPen Auto-Injector and Mylan Specialty markets and distributes the product in the United States.

As per the settlement, Intelliject and Sanofi-Aventis may launch e-cue no earlier than November 15, 2012, subject to receipt of final approval from the U.S. Food and Drug Administration.

Click here to receive FREE breaking news email alerts for Mylan Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After failing to sustain an initial upward move, stocks fluctuated over the course of the trading session on Wednesday before ending the day mixed. The choppy trading came as traders digested upbeat GDP data as well as the Federal Reserve's monetary policy announcement. President Barack Obama took Congress to task in remarks on the economy on Wednesday, accusing Republicans of wasting valuable time by voting on a resolution regarding whether or not to sue him over his use of executive actions. In a surprise move, the Senate voted Tuesday to make changes to an important House highway funding bill, raising questions about whether the legislation will receive final approval before lawmakers leave town for the August recess.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.